Bridging Therapies in ACLF
Bridging therapies in ACLF are used for bridging to liver transplant (LT) and to spontaneous recovery.
Plasma exchange is the most studied and has better evidence of survival improvement in ACLF as compared to other modalities.
Extracorporeal cellular therapy, molecular adsorbent recirculating system and fractionated plasma separation and adsorption therapies have been explored, but studies are small and have shown no survival benefi t. There is poor quality of evidence.
Timing of LT is important in ACLF. Infection, organ failure, logistics, delay in donor availability preclude LT.
Adverse events are volume related. More RCTs are needed to place in a management algorithm.
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article